Patents Assigned to Licentia Ltd
  • Novel Neurotrophic Factor Protein and Uses Thereof
    Publication number: 20100285045
    Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.
    Type: Application
    Filed: December 14, 2006
    Publication date: November 11, 2010
    Applicant: Licentia Ltd
    Inventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen, Merja Voutilainen
  • Neurotrophic factor protein and uses thereof
    Patent number: 7452969
    Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: November 18, 2008
    Assignee: Licentia Ltd
    Inventors: Mart Saarma, Juha Lauren, Päivi Lindholm, Tonis Timmusk, Raimo Tuominen
  • Use of VEGF-C to prevent restenosis
    Patent number: 6958147
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: October 25, 2005
    Assignees: Licentia Ltd, Seppo Yla-Herttuala, Ludwig Institute of Cancer Research
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 6361946
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: March 26, 2002
    Assignees: Licentia Ltd, Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov